Ladenburg Thalmann Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $2

Ladenburg Thalmann analyst Michael Higgins maintains $Ovid Therapeutics(OVID.US)$ with a buy rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate

Futu NewsJul 11 19:31 · Ratings

ENeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibitionOV329 demonstrated

GlobeNewswireJul 10 20:00

Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer

Immunic (IMUX) said Tuesday it has appointed Jason Tardio as chief operating officer and president, starting July 12.Tardio most recently served as chief operating officer at Ovid Therapeutics (OVID),

MT NewswiresJul 9 20:36

TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating

TD Cowen analyst Ritu Baral maintains $Ovid Therapeutics(OVID.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 8.2% over the pas

Futu NewsJul 3 18:31 · Ratings

A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $5

On Jul 02, major Wall Street analysts update their ratings for $Ovid Therapeutics(OVID.US)$, with price targets ranging from $2 to $5.TD Cowen analyst Ritu Baral maintains with a buy rating.BTIG analy

Futu NewsJul 2 21:00 · Ratings

TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TipRanksJul 2 19:26